11 results on '"Hun-Jun Park"'
Search Results
2. Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer
- Author
-
Kyoung Woo Seo, Kiyuk Chang, Hun Jun Park, Jun Won Lee, Hyoung-Mo Yang, Sung Gyun Ahn, Hyo-Soo Kim, Young Jin Youn, Hong-Seok Lim, Wook Sung Chung, Ki Bae Seung, Yoon Seok Koh, Jung-Kyu Han, Myeong-Ho Yoon, Seung-Jea Tahk, Bon Kwon Koo, Kyung Woo Park, Junghan Yoon, Han Mo Yang, Pum Joon Kim, So-Yeon Choi, Byoung-Joo Choi, and Seung Hwan Lee
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Coronary artery disease ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Restenosis ,Internal medicine ,Coronary stent ,Internal Medicine ,medicine ,Clinical endpoint ,030212 general & internal medicine ,Myocardial infarction ,Drug-eluting stents ,Sirolimus ,Unstable angina ,business.industry ,Stent ,medicine.disease ,Cardiology ,Original Article ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background and objectives This trial evaluated the safety and efficacy of the Genoss drug-eluting coronary stent. Methods This study was a prospective, multicenter, randomized trial with a 1:1 ratio of Genoss drug-eluting stent (DES)™ and Promus Element™. Inclusion criteria were the presence of stable angina, unstable angina, or silent ischemia. Angiographic inclusion criteria were de novo coronary stenotic lesion with diameter stenosis >50%, reference vessel diameter of 2.5-4.0 mm, and lesion length ≤40 mm. The primary endpoint was in-stent late lumen loss at 9-month quantitative coronary angiography follow-up. Secondary endpoints were in-segment late lumen loss, binary restenosis rate, death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis during 9 months of follow-up. Results We enrolled 38 patients for the Genoss DES™ group and 39 patients for the Promus Element™ group. In-stent late lumen loss at 9 months was not significantly different between the 2 groups (0.11±0.25 vs. 0.16±0.43 mm, p=0.567). There was no MI or stent thrombosis in either group. The rates of death (2.6% vs. 0%, p=0.494), TLR (2.6% vs. 2.6%, p=1.000), and TVR (7.9% vs. 2.6%, p=0.358) at 9 months were not significantly different. Conclusion This first-in-patient study of the Genoss DES™ stent showed excellent angiographic outcomes for in-stent late lumen loss and major adverse cardiac events over a 9-month follow-up.
- Published
- 2017
3. Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
- Author
-
Dong-Bin Kim, Ji-Won Hwang, and Hun Jun Park
- Subjects
business.industry ,Sodium/Glucose Cotransporter 2 ,Internal Medicine ,Medicine ,Disease ,Pharmacology ,Cardiology and Cardiovascular Medicine ,business - Published
- 2020
4. Clinical Significance of Newly Diagnosed Diabetes Mellitus in the Era of DES for Acute Myocardial Infarction
- Author
-
Hun Jun Park
- Subjects
medicine.medical_specialty ,business.industry ,030204 cardiovascular system & hematology ,medicine.disease ,03 medical and health sciences ,Newly diagnosed diabetes ,Editorial ,0302 clinical medicine ,Internal medicine ,Internal Medicine ,medicine ,Clinical significance ,030212 general & internal medicine ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business - Abstract
After the first acute myocardial infarction (AMI), a considerable proportion of patients are newly diagnosed with diabetes mellitus (DM). However, in AMI, controversy remains regarding the disparity in prognosis between previously diagnosed DM (known-DM) and newly diagnosed DM (new-DM).The study included 10,455 patients with AMI (non-DM, 6,236; new-DM, 659; known-DM, 3,560) admitted to one of 15 participating centers in Korea between November 2011 and January 2016 (average follow-up, 523 days). We compared the characteristics and clinical course of patients with known-DM and those with new- or non-DM.Compared to patients with known-DM, those with new-DM or non-DM were younger, more likely to be male, and less likely to have hypertension, dyslipidemia, prior stroke, angina, or myocardial infarction. Compared to patients with new-DM or non-DM (reference), those with known-DM had higher risks of major adverse cardiac events (hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.06-1.35; p=0.004), cardiac death (HR, 1.26; 95% CI, 1.01-1.57; p=0.042), and congestive heart failure (HR, 1.58; 95% CI, 1.20-2.08). Unlike known-DM, new-DM did not increase the risk of cardiac events (including death).Known-DM was associated with a significantly higher risk of cardiovascular events after AMI, while new-DM had a similar risk of cardiac events as that noted for non-DM. There were different cardiovascular outcomes according to diabetes status in patients with AMI.
- Published
- 2018
5. Clinical, Electrocardiographic, and Procedural Characteristics of Patients With Coronary Chronic Total Occlusions
- Author
-
Dong-Bin Kim, Wook-Seong Chung, Pum-Jun Kim, Jae-Hyung Kim, Chul Soo Park, Chan Seok Park, Hee-Yeol Kim, Ki Bae Seung, Doo-Soo Jeon, Hun-Jun Park, Sang-Hyun Ihm, Ki-Dong Yoo, Jong-Min Lee, and Keon-Woong Moon
- Subjects
medicine.medical_specialty ,Percutaneous ,Bundle branch block ,business.industry ,medicine.medical_treatment ,Angioplasty ,Percutaneous coronary intervention ,medicine.disease ,Revascularization ,Coronary occlusion ,Surgery ,Electrocardiogram ,Angina ,Internal medicine ,T wave ,Internal Medicine ,medicine ,Cardiology ,Original Article ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background and objectives Percutaneous coronary intervention for chronic total occlusion lesions is technically difficult despite equipment advances. Changes in electrocardiographic patterns, such as Q and T waves, during chronic total occlusion can provide information about procedural success and myocardial viability. In this study, we investigated clinical, electrocardiographic, and procedural characteristics of chronic total occlusions. Subjects and methods Patients (2,635) who underwent coronary angiography between January 2006 and July 2007 at six Catholic University Hospitals were identified using a dedicated Internet database. Results A total of 195 patients had total occlusion lesions (7.4%). Percutaneous coronary interventions were attempted in 136 total occlusion lesions (66.0%) in 134 patients. Successful recanalization with stent implantation was accomplished in 89 lesions, with a procedural success rate of 66.4%. One procedure-related death occurred because of no-reflow phenomenon. After excluding 8 patients with bundle branch block, Q and T wave inversions were observed in 60 (32.1%) and 78 patients (41.7%), respectively. The presence of Q waves was associated with severe angina, decreased left ventricular ejection fraction, regional wall motion abnormality, and T wave inversion, but was not related to procedural success. Conclusion Percutaneous coronary intervention is a safe and useful procedure for the revascularization of coronary chronic total occlusion lesions. The procedural success rate was not related to the presence of pathologic Q waves, which were associated with severe angina and decreased left ventricular function.
- Published
- 2009
6. Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation After Coronary Stent Implantation
- Author
-
Beom-June Kwon, Ho-Joong Youn, Man-Young Lee, Jongmin Lee, Ji-Hoon Kim, Wook-Sung Chung, Keon-Woong Moon, Yong-Seog Oh, Eun Joo Cho, Jae-Hyung Kim, Dong-Bin Kim, Ki-Bae Seung, Hun-Jun Park, Sung-Won Jang, Ki-Dong Yoo, Tai-Ho Rho, and Woo-Seung Shin
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Platelet aggregation inhibitors ,Internal medicine ,Angioplasty ,Antithrombotic ,Coronary stent ,Internal Medicine ,medicine ,In patient ,cardiovascular diseases ,business.industry ,Anticoagulants ,Percutaneous coronary intervention ,Atrial fibrillation ,medicine.disease ,surgical procedures, operative ,Conventional PCI ,Cardiology ,Platelet aggregation inhibitor ,Original Article ,Stents ,Cardiology and Cardiovascular Medicine ,business ,therapeutics - Abstract
Background and Objectives Little evidence is available on the optimal antithrombotic therapy following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF). We investigated the outcomes of antithrombotic treatment strategies in AF patients who underwent PCI. Subjects and Methods Three hundred sixty-two patients (68.0% men, mean age: 68.3±7.8 years) with AF and who had undergone PCI with stent implantation between 2005 and 2007 were enrolled. The clinical, demographic and procedural characteristics were reviewed and the stroke risk factors as well as antithrombotic regimens were analyzed. Results The accompanying comorbidities were as follows: hypertension (59.4%), diabetes (37.3%) and congestive heart failure (16.6%). The average number of stroke risk factors was 1.6. At the time of discharge after PCI, warfarin was prescribed for 84 patients (23.2%). Cilostazol was used in addition to dual antiplatelet therapy in 35% of the patients who did not receive warfarin. The mean follow-up period was 615±385 days. The incidences of major adverse cardiac events (MACE), stroke and major bleeding were 11.3%, 3.6% and 4.1%, respectively. By Kaplan-Meier survival analysis, warfarin treatment was not associated with a lower risk of MACE (p=0.886), but it was associated with an increased risk of major bleeding (p=0.002). Conclusion Oral anticoagulation therapy after PCI may increase hemorrhagic events in Korean AF patients.
- Published
- 2011
7. Effect of Adult Bone Marrow Stem Cells on Myocardial Regeneration in Doxorubicin-Induced Mouse Cardiomyopathy
- Author
-
Sang Hong Baek, Ki Bae Seung, Pum-Joon Kim, Hun-Jun Park, Sung-Won Jang, Chan Seok Park, Dong-Bin Kim, Kwan Mo Yang, Kyu-Bo Choi, and Hae Ok Jung
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Cardiomyopathy ,Bone Marrow Stem Cell ,medicine.disease ,Peripheral blood mononuclear cell ,Contractility ,medicine.anatomical_structure ,Fibrosis ,Immunology ,Internal Medicine ,medicine ,Bone marrow ,Stem cell ,Cardiology and Cardiovascular Medicine ,business ,Adult stem cell - Abstract
Background and Objectives: Bone marrow cells have been shown to differentiate into various cell lineages, including cardiomyocytes, in recent studies. This study evaluates the hypothesis that intravenous injection of bone marrow mononuclear cells (BMNCs) into rats with doxorubicin-induced cardiomyopathy can induce myocardial regeneration and improve myocardial contractility. Materials and Methods: Adult male Sprague-Dawley rats were induced to develop cardiomyopathy by treatment with doxorubicin (2.5 mg/kg, 6 times, 2-week period). Stem cell enriched BMNCs were injected into the tail vein of the rats after cessation of the doxorubicin injections. One week after the injection of PKH-67-labeled BMNCs, the localization of transplanted cells was evaluated. Immunohistochemical studies and Western blots were performed two weeks after BMNCs injection. Results: Cell-treated animals showed significant improvement in left ventricular fractional shortening as compared to untreated (control) rats (cell treated group vs. control group 47.2±4.9% vs. 34.4±3.6%, p
- Published
- 2008
8. Effect of High Dose External Irradiation on the Matrix Metalloprotease-2 Expression in a Rat Carotid Artery Injury Model
- Author
-
Sung-Won Jang, Dong-Bin Kim, Tae Kyoon Kim, Sang Hong Baek, Pum-Joon Kim, Hae Ok Jung, Ki Bae Seung, Yong Joo Kim, Hun-Jun Park, Kyu-Bo Choi, and Chan Seok Park
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,Internal Medicine ,medicine ,Cardiology ,External irradiation ,Matrix metalloproteinase ,Carotid artery injury ,Cardiology and Cardiovascular Medicine ,business - Published
- 2008
9. Elevated Troponin I after Implantation of Drug-Eluting Stents: Incidence, Predictors, and Prognostic Value
- Author
-
Hun Jun Park, Sang Hong Baek, Hae Ok Jung, Chan Suk Park, Ki Bae Seung, Kyu Bo Choi, Dong-Bin Kim, Sung Won Jang, Seong Hoon Kim, and Pum Joon Kim
- Subjects
Univariate analysis ,Acute coronary syndrome ,medicine.medical_specialty ,biology ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,Stent ,musculoskeletal system ,medicine.disease ,Troponin ,Internal medicine ,Occlusion ,Conventional PCI ,Troponin I ,cardiovascular system ,Internal Medicine ,biology.protein ,Cardiology ,Medicine ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background and Objectives: The presence of elevated troponin after percutaneous coronary intervention (PCI) is considered to reflect irreversible myocardial injury. However, its prognostic value remains unclear. The purpose of this study was to investigate the incidence, risk factors, and clinical outcomes of troponin I (TnI) elevation after the implantation of drug-eluting stent (DES). Subjects and Methods: We performed a retrospective analysis of 335 patients who had undergone PCI with DES. Patients who had acute coronary syndrome with elevated TnI levels before PCI were excluded. TnI levels were measured 6 and 24 hours after PCI. Results: Baseline clinical characteristics were similar in the elevated TnI and normal TnI groups. Elevated postprocedural TnI (>1.5 ng/mL) occurred in 52 patients (15.5%). Univariate analysis revealed that the clinically significant variables were multi-vessel disease (p
- Published
- 2008
10. Association between the JNC 7 Classification of the Stages of Systolic Hypertension and Inflammatory Cardiovascular Risk Factors
- Author
-
Ki-Bae Seung, Ho-Joong Youn, Ki-Dong Yoo, Hun-Jun Park, Jong-Min Lee, Sung-Won Jang, Jae-Hyung Kim, Hee-Yeol Kim, Sang-Hong Baek, Chan Seok Park, Doo-Soo Jeon, Kyu-Bo Choi, and Sang-Hyun Ihm
- Subjects
medicine.medical_specialty ,National Health and Nutrition Examination Survey ,Systolic hypertension ,business.industry ,Logistic regression ,medicine.disease ,Systemic inflammation ,Prehypertension ,Confidence interval ,Blood pressure ,Internal medicine ,Internal Medicine ,medicine ,Cardiology ,Risk factor ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background and Objectives: It is well known that the higher the blood pressure, the greater the chance of cardiovascular disease, but the factors that are responsible for this association remain largely unknown. We sought to determine whether blood pressure, in a dose-dependent way, is associated with systemic inflammation, which is a known risk factor for cardiovascular events. Subjects and Methods: We analyzed the data from 5,626 participants, aged 40-65 years, of the Third National Health and Nutrition Examination Survey (NHANES III). We quantified the blood pressure by dividing the participants into the normal, pre-, stage 1 and stage 2 hypertension groups based on the Joint National Committee 7 (JNC) classification. We used multiple linear and logistic regression models to determine the relationship between blood pressure and the levels of inflammatory markers. Results: After adjustments were made for various co-morbidities, participants with stage 2 systolic hypertension had higher circulating leukocyte levels [840/μL (95% confidence interval [CI], 374 to 939/μL)] and fibrinogen levels [24.5 mg/dL (95% CI, 8.9 to 31.9 mg/dL)] than those participants with normal blood pressure. They also showed higher circulating C-reactive protein levels (C-reactive protein>10.0 mg/L: p for trend=0.001). There was a dose-dependent increase for the circulating levels of the risk factors across the different levels of systolic blood pressure, but not for diastolic blood pressure. Conclusion: These findings demonstrate that an elevated systolic blood pressure is an independent risk factor for systemic inflammation and this may explain why systolic hypertension is a risk factor for atherosclerosis and cardiovascular events. (Korean Circ J 2007;37:623-629)
- Published
- 2007
11. Intracoronary Stent Deployment without Antiplatelet Agents in a Patient with Idiopathic Thrombocytopenic Purpura
- Author
-
Sang-Hong Baek, Min-Seok Choi, Ki-Bae Seung, Hyun-Hee Kang, Jae-Hyung Kim, Chan Seok Park, Hun-Jun Park, Kyu-Bo Choi, Uk-Hyun Kil, and Pum Joon Kim
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,medicine.disease ,Thrombocytopenic purpura ,Surgery ,Stenosis ,Refractory ,Restenosis ,Internal medicine ,Conventional PCI ,Internal Medicine ,medicine ,Cardiology ,Platelet ,cardiovascular diseases ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business - Abstract
Deciding on the appropriate antiplatelet therapy is a challenge when treating patients with idiopathic thrombocytopenic purpura (ITP) and who are undergoing percutaneous coronary intervention (PCI). We describe here a case of PCI in a patient with chronic, refractory ITP. A 61-year-old woman presented with exertional chest pain and a low platelet count (4×10 9 /L) at admission. Coronary angiography revealed 99% stenosis of the mid left anterior descending artery and 95% stenosis of the mid left circumflex artery. Antiplatelet agents couldn’t be administered because of the risk of bleeding. After transfusion of platelets and administering intravenous immunoglobulin, we deployed baremetal stents in both lesions without administering any antiplatelet agents. Although focal in-stent restenosis developed 5 months later, there was no episode of stent thrombosis despite not using antiplatelet agents. The present case suggests that the rate of stent thrombosis may be lower was previously thought and antiplatelet therapy may be considered on a case by case for patient suffering with thrombocytopenia. (Korean Circulation J 2007;37:87-90)
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.